Aethlon Medical, a San Diego company, named Timothy Rodell as interim CEO, it was announced Dec. 13.

Rodell was previously the CEO of Colorado-based GlobeImmune, which was acquired by NantCell. He succeeds James Joyce, who will act as an Aethlon consultant during the transition.

Aethlon’s clinical-stage Hemopurifier is designed for cancer and life-threatening viral infections. The device received a Food and Drug Administration “breakthrough device” designation, which could ease the company's regulatory path.

Rodell officially took the reins Dec. 10.